Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 2/20 | 0.44 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | EDNRB | P24530 | 1/20 | 0.35 |
| ▸ | EDNRA | P25101 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2729130 | 0.83 | CES1 (0.46) | CES1KCNN4HIF1ACYP2C19CYP1A2 | |
| SCHEMBL28481278 | 0.82 | PIN1 (0.46) | CES1KCNN4KMT2AMAPTALDH1A1 | |
| SCHEMBL28753479 | 0.81 | CES1 (0.44) | CES1KCNN4HIF1ACYP2C19CYP1A2 | |
| SCHEMBL6387363 | 0.81 | CYP2C19 (0.53) | CES1KCNN4HIF1ACYP2C19CYP1A2 | |
| SCHEMBL7924474 | 0.81 | CES1 (0.44) | CES1KCNN4HIF1ACYP2C19CYP1A2 | |
| SCHEMBL11775673 | 0.77 | ALDH1A1 (0.57) | CES1KCNN4HIF1ACYP2C19CYP1A2 | |
| SCHEMBL25477181 | 0.77 | ALDH1A1 (0.52) | CES1KCNN4HIF1ACYP2C19CYP1A2 | |
| SCHEMBL18496747 | 0.76 | CHRM3 (0.43) | CES1KCNN4HIF1ACYP2C19CHRM2 | |
| SCHEMBL6372896 | 0.76 | KCNN4 (0.46) | CES1KCNN4HIF1ACYP2C19CYP1A2 | |
| SCHEMBL6372894 | 0.76 | KCNN4 (0.46) | CES1KCNN4HIF1ACYP2C19CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-218475764-U | Photovoltaic and photo-thermal integrated garbage bin | 光大环境科技（中国）有限公司 | 2023-02-14 | — | — | CN | claimed |
| US-6451334-B2 | PULSE ADMINISTERING OF A C1-C4 SUBSTITUTED AND/OR PHENYL SUBSTITUTED CARBOXYLIC ACID AND SALTS AND A CARRIER OR DILUENT TO STIMULATE CELLS IN TREATING BLOOD DISORDERS, E.G. SICKLE CELL ANEMIA, THALASSEMIA, BLOOD LOSS ETC. | Perrine, Susan P. | 2002-09-17 | — | — | US | claimed |
| CN-117986582-A | Bio-based high-toughness self-repairing flexible resin and preparation method thereof | 江南大学 | 2024-05-07 | — | — | CN | disclosed |
| CN-117597327-A | Pharmaceutical preparation | 第一波动生物制药股份有限公司 | 2024-02-23 | — | — | CN | disclosed |
| CN-112105610-B | Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation | 朱比连特普罗德尔有限责任公司 | 2024-01-26 | — | — | CN | disclosed |
| CN-218475764-U | Photovoltaic and photo-thermal integrated garbage bin | 光大环境科技（中国）有限公司 | 2023-02-14 | — | — | CN | disclosed |
| US-11529341-B2 | Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation | Jubilant Prodel LLC | 2022-12-20 | — | — | US | disclosed |
| CN-112105610-A | Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation | 朱比连特普罗德尔有限责任公司 | 2020-12-18 | — | — | CN | disclosed |
| US-7649015-B2 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2010-01-19 | — | — | US | disclosed |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | GILEAD SCIENCES, INC. | 2007-01-11 | — | — | US | disclosed |
| EP-1711617-A1 | METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTICS COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2006-10-18 | — | — | EP | disclosed |
| WO-2005064008-A9 | METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS | GILEAD SCIENCES INC (US) | 2006-09-28 | — | — | WO | disclosed |
| US-20050239054-A1 | Method and compositions for identifying anti-HIV therapeutic compounds | GILEAD SCIENCES. INC. | 2005-10-27 | — | — | US | disclosed |
| US-20050209197-A1 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | GILEAD SCIENCES, INC. | 2005-09-22 | — | — | US | disclosed |
| WO-2005064008-A1 | METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| EP-1509537-A2 | CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH | GILEAD SCIENCES, INC. (US) | 2005-03-02 | — | — | EP | disclosed |
| WO-2003090690-A2 | CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH | GILEAD SCIENCES, INC. (US) | 2003-11-06 | — | — | WO | disclosed |
| US-6451334-B2 | PULSE ADMINISTERING OF A C1-C4 SUBSTITUTED AND/OR PHENYL SUBSTITUTED CARBOXYLIC ACID AND SALTS AND A CARRIER OR DILUENT TO STIMULATE CELLS IN TREATING BLOOD DISORDERS, E.G. SICKLE CELL ANEMIA, THALASSEMIA, BLOOD LOSS ETC. | Perrine, Susan P. | 2002-09-17 | — | — | US | disclosed |
| US-20010027215-A1 | Compositions and administration of compositions for the treatment of blood disorders | SUSAN PERRINE | 2001-10-04 | — | — | US | disclosed |
| US-6231880-B1 | ANTIGROWTH AGENTS FOR CELLS BY STIMULATING TO PATIENTS AND EFFECTIVE DIMETHYL SUBSTITUTED CARBOXYLIC ACID | Perrine, Susan P. | 2001-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209197-A1 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | PPA1, PPME1, PNP | CES1 578/4885KCNN4 4736/4885HIF1A 3944/4885 |
| US-20050239054-A1 | Method and compositions for identifying anti-HIV therapeutic compounds | CES1, PNP, PGLS | CES1 1/4885KCNN4 4386/4885HIF1A 4185/4885 |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | PPA1, PNP, PPME1 | CES1 565/4885KCNN4 4722/4885HIF1A 4003/4885 |
| US-11529341-B2 | Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation | CD274, PDCD1, PDCD1LG2 | CES1 615/4885KCNN4 4623/4885HIF1A 1533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.